Dual function antibody targeting αvβ3 and PD-L1 provide a promising strategy for solid tumor therapy.
Saved in:
| Title: | Dual function antibody targeting αvβ3 and PD-L1 provide a promising strategy for solid tumor therapy. |
|---|---|
| Authors: | Li G; Pharmacology and Toxicology Research Department, Tasly Research Center, Tasly Pharmaceutical Group Co., Ltd., Tianjin, China., Li W; Biologics Development Department, Tasly Research Center, Tasly Pharmaceutical Group Co., Ltd., Tianjin, China., Wang L; Pharmacology and Toxicology Research Department, Tasly Research Center, Tasly Pharmaceutical Group Co., Ltd., Tianjin, China., Bi Y; Pharmacology and Toxicology Research Department, Tasly Research Center, Tasly Pharmaceutical Group Co., Ltd., Tianjin, China., Wang Y; Biologics Development Department, Tasly Research Center, Tasly Pharmaceutical Group Co., Ltd., Tianjin, China., Zheng X; Pharmacology and Toxicology Research Department, Tasly Research Center, Tasly Pharmaceutical Group Co., Ltd., Tianjin, China., Hao R; Pharmacology and Toxicology Research Department, Tasly Research Center, Tasly Pharmaceutical Group Co., Ltd., Tianjin, China., Yin Y; Biologics Development Department, Tasly Research Center, Tasly Pharmaceutical Group Co., Ltd., Tianjin, China., Yu Y; Biologics Development Department, Tasly Research Center, Tasly Pharmaceutical Group Co., Ltd., Tianjin, China., Mu H; Biologics Development Department, Tasly Research Center, Tasly Pharmaceutical Group Co., Ltd., Tianjin, China., Li J; Biologics Development Department, Tasly Research Center, Tasly Pharmaceutical Group Co., Ltd., Tianjin, China., Ma X; Pharmacology and Toxicology Research Department, Tasly Research Center, Tasly Pharmaceutical Group Co., Ltd., Tianjin, China., Zhou S; Pharmacology and Toxicology Research Department, Tasly Research Center, Tasly Pharmaceutical Group Co., Ltd., Tianjin, China., Han J; Tasly Biopharmaceuticals Co., Ltd., Tianjin, China., Wang G; Pharmacology and Toxicology Research Department, Tasly Research Center, Tasly Pharmaceutical Group Co., Ltd., Tianjin, China., Huang R; Biologics Development Department, Tasly Research Center, Tasly Pharmaceutical Group Co., Ltd., Tianjin, China. |
| Source: | Frontiers in immunology [Front Immunol] 2026 Jan 12; Vol. 16, pp. 1691774. Date of Electronic Publication: 2026 Jan 12 (Print Publication: 2025). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
